Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Abstract

Although small molecule tyrosine kinase inhibitors are effective in lung cancer driven by mutated EGFR, some receptor variants fail to respond. Here, the authors identify structural features of an important set of EGFR variants with reduced inhibitor sensitivity, guiding future inhibitor selection.